Based on the patient’s HBV DNA test results, hepatitis B carriers can be divided into two types: 1. Chronic asymptomatic virus carriers: These patients are HBV DNA positive and will develop hepatitis activity when immune tolerance is broken, which in turn will also have the risk of developing cirrhosis and liver cancer. Therefore, such patients should undergo routine blood, liver function, HBV DNA, methemoglobin, hepatobiliary and splenic ultrasound and non-invasive liver fibrosis tests every 3-6 months, and if they meet the indications for antiviral therapy, treatment should be initiated promptly. 2. Inactive HBsAg carriers: These patients are only positive for hepatitis B surface antigen and have undetectable HBV DNA in the blood, so they do not need treatment either. However, such patients also have the possibility of developing chronic hepatitis B. Moreover, long-term follow-up also reveals that very few patients can develop liver cancer. Therefore, routine blood tests, liver function, HBV DNA, alpha-fetoprotein, hepatobiliary and splenic ultrasound and non-invasive liver fibrosis tests are also recommended every 6 months, and treatment should also be initiated promptly if the indications for antiviral therapy are met.